Current and Future Treatment Strategies for Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, and can be subcategorized histologically and/or based on PAX-FOXO1 fusion gene status. Over the last four decades, there have been no significant improvements in clinical outcomes for advanced and metastatic RMS patients, und...
Main Authors: | Celine Chen, Heathcliff Dorado Garcia, Monika Scheer, Anton G. Henssen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.01458/full |
Similar Items
-
The significance of margins in pediatric Non‐Rhabdomyosarcoma soft tissue sarcomas: Consensus on surgical margin definition harmonization from the INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT)
by: Monika Sparber‐Sauer, et al.
Published: (2023-05-01) -
Radiomic features as biomarkers of soft tissue paediatric sarcomas: preliminary results of a PET/MR study
by: Giraudo Chiara, et al.
Published: (2022-03-01) -
Long-Term Clinical Outcome and Prognostic Factors of Children and Adolescents with Localized Rhabdomyosarcoma Treated on the CWS-2002P Protocol
by: Ewa Koscielniak, et al.
Published: (2022-02-01) -
Pediatric rhabdomyosarcoma incidence and survival in the United States: An assessment of 5656 cases, 2001–2017
by: Matthew T. McEvoy, et al.
Published: (2023-02-01) -
Oral vinorelbine and continuous low doses of cyclophosphamide in pediatric rhabdomyosarcoma: a real-world study
by: Yingxia Lan, et al.
Published: (2023-05-01)